Goldman Sachs Group Inc Evelo Biosciences, Inc. Transaction History

Goldman Sachs Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 14, 2024	SELL	$0.17 - $1.57 $958 - $8,856	-5,641 Reduced 18.0%	25,695 $4,000
Q1 2023 May 11, 2023	SELL	$0.17 - $1.57 $958 - $8,856	-5,641 Reduced 18.0%	25,695 $4,000
Q4 2022 May 14, 2024	SELL	$1.44 - $48.2 $3,929 - $131,537	-2,729 Reduced 8.01%	31,336 $50,000
Q4 2022 Feb 13, 2023	SELL	$1.44 - $48.2 $3,929 - $131,537	-2,729 Reduced 8.01%	31,336 $50,000
Q3 2022 May 14, 2024	SELL	$1.86 - $41.8 $14,831 - $333,313	-7,974 Reduced 18.97%	34,065 $71,000
Q3 2022 Nov 10, 2022	SELL	$1.86 - $41.8 $14,831 - $333,313	-7,974 Reduced 18.97%	34,065 $0
Q2 2022 May 14, 2024	BUY	$1.46 - $3.55 $61,376 - $149,238	42,039 New	42,039 $89,000
Q2 2022 Aug 15, 2022	SELL	$1.46 - $3.55 $17,403 - $42,316	-11,920 Reduced 22.09%	42,039 $89,000
Q1 2022 May 16, 2022	BUY	$2.66 - $6.63 $10,911 - $27,196	4,102 Added 8.23%	53,959 $183,000
Q4 2021 Feb 14, 2022	BUY	$6.07 - $12.0 $68,985 - $136,380	11,365 Added 29.53%	49,857 $302,000
Q3 2021 Nov 10, 2021	BUY	$6.79 - $13.9 $261,360 - $535,038	38,492 New	38,492 $271,000

Ticker EVLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,994,000
Description
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hy...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.